SEARCH

SEARCH BY CITATION

References

  • 1
    Dieckgraefe BK, Stenson WF, Korzenik JR, Swanson PE, Harrington CA. Analysis of mucosal gene expression in inflammatory bowel disease by parallel oligonucleotide arrays. Physiol Genomics 2000; 4: 111.
  • 2
    Uthoff SM, Eichenberger MR, Lewis RK, et al. Identification of candidate genes in ulcerative colitis and Crohn's disease using cDNA array technology. Int J Oncol 2001; 19: 80310.
  • 3
    Lawrance IC, Fiocchi C, Chakravarti S. Ulcerative colitis and Crohn's disease: distinctive gene expression profiles and novel susceptibility candidate genes. Hum Mol Genet 2001; 10: 44556.
  • 4
    Langmann T, Moehle C, Mauerer R, et al. Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes. Gastroenterology 2004; 127: 2640.
  • 5
    Schachter H, Kirsner JB. Definitions of inflammatory bowel disease of unknown etiology. Gastroenterology 1975; 68: 591600.
  • 6
    Riley SA, Mani V, Goodman MJ, et al. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology 1988; 94: 13839.
  • 7
    Riley SA, Mani V, Goodman MJ, et al. Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate UC relapse. Gut 1988; 29: 66974.
  • 8
    Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001; 98: 511621.
  • 9
    Peirson SN, Butler JN, Foster RG. Experimental validation of novel and conventional approaches to quantitative real-time PCR data analysis. Nucleic Acids Res 2003; 31: e73.
  • 10
    Salmela MT, MacDonald TT, Black D, et al. Upregulation of matrix metalloproteinases in a model of T cell mediated tissue injury in the gut: analysis by gene array and in situ hybridization. Gut 2002; 51: 5407.
  • 11
    Pender SL, Fell JM, Chamow SM, Ashkenazi A, MacDonald TT. A p55 TNF receptor immunoadhesin prevents T cell-mediated intestinal injury by inhibiting matrix metalloproteinase production. J Immunol 1998; 160: 4098103.
  • 12
    Adeyemi EO, Hodgson HJF. Fecal elastase reflects disease activity in active ulcerative colitis. Scand J Gastroenterol 1992; 27: 13942.
  • 13
    Ottonello L, Dapino P, Pastorino G, et al. The drug 5-aminosalicylic acid rescues α(1)-proteinase inhibitor from the neutrophil oxidative inactivation – a possible contribution to its therapeutic action in ulcerative-colitis. Digestion 1992; 51: 1405.
  • 14
    Kuno Y, Ina K, Nishiwaki T, et al. Possible involvement of neutrophil elastase in impaired mucosal repair in patients with UC. J Gastroenterol 2002; 37: 2232.
  • 15
    Henriksen PA, Devitt A, Kotelevsev Y, et al. Gene delivery of the elastase inhibitor elafin protects macrophages from neutrophil elastase-mediated impairment of apoptotic cell recognition. FEBS Lett 2004; 574: 804.
  • 16
    Kerkhoff C, Klempt M, Sorg C. Novel insights into structure and function of MRP8 (S100A8) and MRP14 (S100A9). Biochim Biophys Acta 1998; 1448: 20011.
  • 17
    Yang SK, Choi MS, Kim OH, et al. The increased expression of an array of C-X-C and C-C chemokines in the colonic mucosa of patients with UC: regulation by corticosteroids. Am J Gastroenterol 2002; 97: 12632.
    Direct Link:
  • 18
    Molmenti EP, Ziambaras T, Perlmutter DH. Evidence for an acute phase response in human intestinal epithelial cells. J Biol Chem 1993; 268: 1411624.
  • 19
    Vreugdenhil AC, Dentener MA, Snoek AM, Greve JW, Buurman WA. Lipopolysaccharide binding protein and serum amyloid A secretion by human intestinal epithelial cells during the acute phase response. J Immunol 1999; 163: 27928.
  • 20
    Costa F, Mumolo MG, Bellini M, et al. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis 2003; 35: 6427.
  • 21
    Niederau C, Backmerhoff F, Schumacher B, Niederau C. Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis. Hepatogastroenterology 1997; 44: 90107.
  • 22
    Pfundt R, Ruissen FV, van Vlijmen-Willems IMJJ, et al. Constitutive and inducible expression of SKALP/Elafin provides anti-elastase defense in human epithelia. J Clin Invest 1996; 98: 138999.
  • 23
    Simpson AJ, Wallace WAH, Marsden ME, et al. Adenoviral augmentation of elafin protects the lung against acute injury mediated by activated neutrophils and bacterial infection. J Immunol 2001; 167: 177886.
  • 24
    Matsuno K, Adachi Y, Yamamoto H, et al. The expression of matrix metalloproteinase matrilysin indicates the degree of inflammation in UC. J Gastroenterol 2003; 38: 34854.
  • 25
    von Lampe B, Barthel B, Coupland SE, Riecken EO, Rosewicz S. Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut 2000; 47: 6373.
  • 26
    Louis E, Ribbens C, Godon A, et al. Increased production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by inflamed mucosa in inflammatory bowel disease. Clin Exp Immunol 2000; 120: 2416.
  • 27
    Pelsers MM, Namiot Z, Kisielewski W, et al. Intestinal-type and liver-type fatty acid-binding protein in the intestine. Tissue distribution and clinical utility.Clin Biochem 2003; 36: 52935.
  • 28
    Memon RA, Bass NM, Moser AH, et al. Down-regulation of liver and heart specific fatty acid binding proteins by endotoxin and cytokines in vivo. Biochim Biophys Acta 1999; 1440: 11826.
  • 29
    Roediger WE. The colonic epithelium in ulcerative colitis: an energy-deficiency disease? Lancet 1980; 2: 7125.
  • 30
    Flower DR. The lipocalin protein family: structure and function. Biochem J 1996; 318(Pt 1): 114.
  • 31
    Carlson M, Raab Y, Seveus L, et al. Human neutrophil lipocalin is a unique marker of neutrophil inflammation in ulcerative colitis and proctitis. Gut 2002; 50: 5016.
  • 32
    Peterson CG, Eklund E, Taha Y, Raab Y, Carlson M. A new method for the quantification of neutrophil and eosinophil cationic proteins in feces: establishment of normal levels and clinical application in patients with inflammatory bowel disease. Am J Gastroenterol 2002; 97: 175562.
    Direct Link:
  • 33
    Kocher O, Cheresh P, Lee SW. Identification and partial characterization of a novel membrane-associated protein (MAP17) up-regulated in human carcinomas and modulating cell replication and tumor growth. Am J Pathol 1996; 149: 493500.
  • 34
    Kocher O, Comella N, Tognazzi K, Brown LF. Identification and partial characterization of PDZK1: a novel protein containing PDZ interaction domains. Lab Invest 1998; 78: 11725.
  • 35
    Rio MC, Bellocq JP, Daniel JY, et al. Breast cancer-associated pS2 protein: synthesis and secretion by normal stomach mucosa. Science 1988; 241: 7058.
  • 36
    Pera M, Heppell J, Poulsom R, Teixeira FV, Williams J. Ulcer associated cell lineage glands expressing trefoil peptide genes are induced by chronic ulceration in ileal pouch mucosa. Gut 2001; 48: 7926.
  • 37
    Podolsky DK. Mechanisms of regulatory peptide action in the gastrointestinal tract: trefoil peptides. J Gastroenterol 2000; 35 (Suppl.12): 6974.
  • 38
    Longman RJ, Douthwaite J, Sylvester PA, et al. Coordinated localisation of mucins and trefoil peptides in the ulcer associated cell lineage and the gastrointestinal mucosa. Gut 2000; 47: 792800.
  • 39
    Lefebvre O, Chenard MP, Masson R, et al. Gastric mucosa abnormalities and tumorigenesis in mice lacking the pS2 trefoil protein. Science 1996; 274: 25962.
  • 40
    Medina D. Mechanisms of selenium inhibition of tumorigenesis. Adv Exp Med Biol 1986; 206: 46572.